Two Democratic congressmen are raising questions about whether Mylan NV, the company facing backlash for raising the price of its EpiPen device, overcharged the government’s Medicaid program for the allergy treatment. ADVERTISEMENTSen. Ron WydenRon WydenDems call for probe into EpiPen maker’s Medicaid charges Treasury Section 385 proposal would hurt job-creating investments 5 takeaways from the EU’s blockbuster ruling against Apple MORE (D-Ore.) and Rep. Frank Pallone (D-N.J.) wrote a letter to the secretary of Department of Health and Human Services asking for clarification on whether EpiPen was considered a generic, “non-innovator” drug, or a brand-name drug by the Medicaid program, according to Reuters. Current law states that branded drugs and generic drugs available from a single source must pay a rebate amount of at least 23.1 percent of the average manufacturer price, while generic drugs are subject to a 13 percent rebate, according to Reuters. Mylan said in a statement to Reuters that …
Go to Source
Dems call for probe into EpiPen maker's Medicaid charges – The Hill (blog)